Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term ADENOCARCINOMA. Found 10 abstracts

Kadariya Y, Yin B, Tang BQ, Shinton SA, Quinlivan EP, Hua X, Klein-Szanto A, Al-Saleem TI, Bassing CH, Hardy RR, Kruger WD. Mice Heterozygous for Germ-line Mutations in Methylthioadenosine Phosphorylase (MTAP) Die Prematurely of T-Cell Lymphoma. Cancer Research. 2009 Jul;69(14):5961-9.   PMCID: PMC2757012
Ahmed MM, Sheldon D, Fruitwala MA, Venkatasubbarao K, Lee FY, Gupta S, Wood C, Mohiuddin M, Strodel WE. Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation. International journal of cancer. 2008 Jan;122(1):63-70.
Berger AC, Garcia M, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB, MacDonald J, Willett CG. Postresection CA 19-9 Predicts Overall Survival in Patients With Pancreatic Cancer Treated With Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704. Journal of Clinical Oncology. 2008 Dec;26(36):5918-22.
Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Lin DW, Anscher MS, Slawin KM, Roehrborn CG, Forman JD, Liauw SL, Kestin LL, DeWeese TL, Scardino PT, Stephenson AJ, Pollack A. A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer. Urology. 2008 Dec;72(6):1298-302.
Che M, Desilvio M, Pollack A, Grignon DJ, Mohan Venkatesan V, Hanks GE, Sandler HM. Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: A study based on RTOG 9202. International Journal of Radiation Oncology Biology Physics. 2007 Nov;69(4):1117-23.
Henry LR, Sigurdson E, Ross EA, Lee JS, Watson JC, Cheng JD, Freedman GM, Konski A, Hoffman JP. Resection of isolated pelvic recurrences after colorectal surgery: Long-term results and predictors of improved clinical outcome. Annals of Surgical Oncology. 2007 Mar;14(3):1081-91.
Sariya D, Ruth K, Adams-McDonnell R, Cusack C, Xu X, Elenitsas R, Seykora J, Pasha T, Zhang P, Baldassano M, Lessin SR, Wu H. Clinicopathologic correlation of cutaneous metastases - Experience from a cancer center. Archives of Dermatology. 2007 May;143(5):613-20.
Travis WD, Garg K, Franklin WA, Wistuba, Sabloff B, Noguchi M, Kakinuma R, Zakowski M, Ginsberg M, Padera R, Jacobson F, Johnson BE, Hirsch F, Brambilla E, Flieder DB, Geisinger KR, Thunnissen F, Kerr K, Yankelevitz D, Franks TJ, Galvin JR, Henderson DW, Nicholson AG, Hasleton PS, Roggli V, Tsao MS, Cappuzzo F, Vazquez M. Bronchioloalveolar carcinoma and lung adenocarcinoma: The clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. Journal of Thoracic Oncology. 2006 Nov;1(9):S13-S19.
Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):915-28.
Kuban D, Pollack A, Huang E, Levy L, Dong L, Starkschall G, Rosen I. Hazards of dose escalation in prostate cancer radiotherapy. International Journal of Radiation Oncology Biology Physics. 2003 Dec;57(5):1260-8.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term ADENOCARCINOMA

ADENOCARCINOMA CARCINOMA CANCER GENE KeyWords Plus: RADICAL PROSTATECTOMY prostate cancer RADIATION-THERAPY IRRADIATION RANDOMIZED-TRIAL long-term outcome GROUND-GLASS OPACITY RECTAL-CANCER CURATIVE RESECTION HUMAN BREAST-CANCER BIOCHEMICAL FAILURE dose escalation H-RAS PROGNOSTIC-SIGNIFICANCE pathology THERAPY CYTOKERATIN 5 SMALL-BOWEL LATE RECTAL TOXICITY PREDICTION POSTTREATMENT EVALUATION Immunohistochemistry Locally ZOSTERIFORM METASTASIS BREAST FREQUENT SOMATIC MUTATIONS lung cancer CONFORMAL RADIOTHERAPY THIN-SECTION CT BIOCHEMICAL CONTROL HIGH-RESOLUTION CT BCL-2 EPITHELIAL-CELLS colorectal cancer PYOGENIC GRANULOMA ASSOCIATION SERUM CA-19-9 PSA-DFS CDKN2 SURGICAL SALVAGE CELL CARCINOMA radiology p53 CODELETION EFFICACY bronchioloalveolar carcinoma complications ONCOGENIC RAS GENE DELETION FAILURE ANTIGEN pancreatic cancer PAR-4-K-ras mutation-survival ORNITHINE-DECARBOXYLASE ANTIGENS pelvis PROGRAMMED CELL-DEATH recurrence VOLUME HISTOGRAMS HOMOZYGOUS DELETIONS RTOG 9202 CONFORMAL RADIATION-THERAPY PROTEIN PAR-4 RECURRENCE FILLED TISSUE EXPANDERS P53 TRIAL Androgen deprivation and radiotherapy PERIPHERAL CHEMOTHERAPY DEFICIENCY resection MUTATION P63 EXPRESSION radiotherapy COMPUTED-TOMOGRAPHY RANDOMIZED CONTROLLED-TRIAL RADIOTHERAPY classification GEMCITABINE FACTOR-BETA RECEPTORS adenocarcinoma NUCLEAR ACCUMULATION SKIN PATTERNS DIAGNOSIS ADNEXAL NEOPLASMS multi-institutional analysis SURVIVAL PROTEIN IMMUNOREACTIVITY Prognostic factor CURATIVE SURGERY TUMOR-SUPPRESSOR RECEPTOR 6 advanced prostate cancer LOCAL AMERICAN SOCIETY GEFITINIB MANAGEMENT
Last updated on Wednesday, February 05, 2020